ProductsClinical ResultsPractitionersTestimonialsVideosHow to BuyCompany News

Press Releases

Prominent New Jersey Surgeon Confirms Bovine Carotid Artery Graft Has Superior Patency to ePTFE

12/20/2011
Mountainside Hospital Division Chief of Surgery Experiences Success with Artegraft® for Nearly a Decade
 

North Brunswick, NJ – November 2011 — A leading surgeon in New Jersey supports the results of a recently published clinical study confirming long-term patency advantages of the Artegraft® Bovine Carotid Artery (BCA) graft over ePTFE synthetic grafts. Division Chief of Surgery at Mountainside Hospital in Montclair, N.J. Dr. Donald Syracuse states the published results are similar to what he has experienced during his nine years of using Artegraft with his patients.

Dr. Syracuse, also a Senior Partner at the Cardiovascular Care Group in Clifton, NJ, began using Artegraft in 2002. He and his colleagues were seeking a better alternative to ePTFE grafts, which they found had unacceptable rates of thrombosis and overall complications. Dr. Syracuse credits the appeal of being "home grown in New Jersey" as what initially drew him to Artegraft, however it has been the results that have made him continue to use Artegraft for nearly a decade.

"There are many reasons we've hit upon and not turned back from our use of Artegraft," said Dr. Syracuse. "I like to look at it, as I believe most surgeons would, in preoperative, operative and postoperative issues. Taking all those phases into consideration, Artegraft has been a good performer for us."

The "Fistula First" initiative is considered to be the initial alternative for establishing access to a patient’s circulatory system. While Dr. Syracuse does follow that protocol, he also believes that there are many patients who are not candidates for fistulas. For example, a patient who is susceptible to infection, has very poor skin turgor or someone with very small vessels that are inappropriate for development of fistulas would be determined preoperatively by Dr. Syracuse and his colleagues as better candidates for Artegraft.

From an intraoperative standpoint, Dr. Syracuse refers to Artegraft as a superior handling graft, primarily because it feels like real tissue. He added, "We've gone away from using many of the so-called haemostatic agents, such as Surgicel®, Gelfoam® and topical thrombin, which we had to use in great detail with the ePTFE grafts. We just don’t need them with the Artegraft."

Dr. Syracuse's experience with Artegraft has also revealed more manageable postoperative care. Patients with an Artegraft can be accessed within two weeks and if an infection does develop in these patients, a local excision—as opposed to complete extirpation, which is necessary with an ePTFE graft—will often suffice.

Artegraft's natural collagen graft, commonly known as the Bovine Graft™ or "Fistula in a Bottle™," has proven long-term patency advantages over ePTFE synthetic grafts. The three-year prospective, randomized clinical study, published in the June 2011 issue of the Journal of Vascular Surgery that caught Dr. Syracuse's eye, confirms the superiority of Artegraft BCA to cuffed ePTFE grafts. The study concluded that the BCA graft had significantly higher primary and assisted patency rates than the ePTFE graft, making Artegraft an excellent option for patients on hemodialysis.

For more information on Artegraft and to see more from Dr. Syracuse, please visit www.artegraft.com.


Artegraft - Press Releases

Sign up for Artegraft News - Our online newsletter Frequently Asked Questions Our Manufacturing Process